These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11412879)

  • 1. Color vision deficiencies in Gilles de la Tourette syndrome.
    Melun JP; Morin LM; Muise JG; DesRosiers M
    J Neurol Sci; 2001 May; 186(1-2):107-10. PubMed ID: 11412879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Farnsworth-Munsell 100 hue test norms of normal observers for each year of age 5-22 and for age decades 30-70.
    Kinnear PR; Sahraie A
    Br J Ophthalmol; 2002 Dec; 86(12):1408-11. PubMed ID: 12446376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Color-axis determination on the Farnsworth-Munsell 100-hue test.
    Smith VC; Pokorny J; Pass AS
    Am J Ophthalmol; 1985 Jul; 100(1):176-82. PubMed ID: 3874549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distorted colour discrimination in Parkinson's disease is related to severity of the disease.
    Müller T; Kuhn W; Büttner T; Przuntek H
    Acta Neurol Scand; 1997 Nov; 96(5):293-6. PubMed ID: 9404998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of color perception in individuals addicted to narcotic substances in the Farnsworth-Munsell 100-Hue test].
    Nadolska K; Goś R
    Med Pr; 2016 Dec; 67(6):777-785. PubMed ID: 28005086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnsworth-Munsell 100-hue test for patients with diabetes mellitus.
    Utku D; Atmaca LS
    Ann Ophthalmol; 1992 Jun; 24(6):205-8. PubMed ID: 1444079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Color vision in glaucoma].
    Bartos D
    Cesk Oftalmol; 1990 May; 46(3):194-207. PubMed ID: 2354536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of visual dysfunction in Parkinson's disease.
    Müller T; Woitalla D; Peters S; Kohla K; Przuntek H
    Acta Neurol Scand; 2002 Apr; 105(4):256-60. PubMed ID: 11939937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered perceptual binding in Gilles de la Tourette syndrome.
    Beste C; Tübing J; Seeliger H; Bäumer T; Brandt V; Stock AK; Münchau A
    Cortex; 2016 Oct; 83():160-6. PubMed ID: 27544346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Color vision defect type and spatial vision in the optic neuritis treatment trial.
    Schneck ME; Haegerstrom-Portnoy G
    Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2278-89. PubMed ID: 9344351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired color vision in cocaine-withdrawn patients.
    Desai P; Roy M; Roy A; Brown S; Smelson D
    Arch Gen Psychiatry; 1997 Aug; 54(8):696-9. PubMed ID: 9283503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Richmond HRR 4th edition and Farnsworth-Munsell 100 Hue Test for quantitative assessment of tritan color deficiencies.
    Foote KG; Neitz M; Neitz J
    J Opt Soc Am A Opt Image Sci Vis; 2014 Apr; 31(4):A186-8. PubMed ID: 24695168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia, color vision deficiencies, and blood oxygen saturation.
    Hovis JK; Milburn NJ; Nesthus TE
    J Opt Soc Am A Opt Image Sci Vis; 2012 Feb; 29(2):A268-74. PubMed ID: 22330388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomograms for the assessment of Farnsworth-Munsell 100-hue test scores.
    Han DP; Thompson HS
    Am J Ophthalmol; 1983 May; 95(5):622-5. PubMed ID: 6601911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gilles de la Tourette syndrome and disruptive behavior disorders: prevalence, associations, and explanation of the relationships.
    Robertson MM; Cavanna AE; Eapen V
    J Neuropsychiatry Clin Neurosci; 2015; 27(1):33-41. PubMed ID: 25162416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of acquired color vision in multiple sclerosis: an early diagnostic sign linked to the greatness of disease.
    Piro A; Tagarelli A; Nicoletti G; Scannapieco S; Polidoro S; Valentino P; Quattrone A
    Int Ophthalmol; 2019 Mar; 39(3):671-676. PubMed ID: 29392642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome.
    Kanaan AS; Gerasch S; García-García I; Lampe L; Pampel A; Anwander A; Near J; Möller HE; Müller-Vahl K
    Brain; 2017 Jan; 140(1):218-234. PubMed ID: 28007998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New iPAD-based test for the detection of color vision deficiencies.
    de Fez D; Luque MJ; Matea L; Piñero DP; Camps VJ
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2349-2360. PubMed ID: 30291435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Farnsworth-Munsell 100-Hue, the Farnsworth D-15, and the L'Anthony D-15 desaturated color tests.
    Bassi CJ; Galanis JC; Hoffman J
    Arch Ophthalmol; 1993 May; 111(5):639-41. PubMed ID: 8489445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome.
    Worbe Y; Marrakchi-Kacem L; Lecomte S; Valabregue R; Poupon F; Guevara P; Tucholka A; Mangin JF; Vidailhet M; Lehericy S; Hartmann A; Poupon C
    Brain; 2015 Feb; 138(Pt 2):472-82. PubMed ID: 25392196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.